Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;34 Suppl 1(Suppl1):35-37.
doi: 10.37201/req/s01.10.2021. Epub 2021 Sep 30.

Ceftolozane-tazobactam: When, how and why using it?

I López Montesinos, M Montero, L Sorlí, J P Horcajada  1
Affiliations
Review

Ceftolozane-tazobactam: When, how and why using it?

I López Montesinos et al. Rev Esp Quimioter. 2021 Sep.

Abstract

Ceftolozane-tazobactam is currently the most active antipseudomonal agent, including multidrug-resistant extensively drug-resistant strains. Tazobactam provides additional activity against many extended-spectrum beta-lactamases Enterobacterales. Ceftolozane-tazobactam is formally approved for complicated urinary tract infection, complicated intra-abdominal infection, and hospital-acquired and ventilator-associated bacterial pneumonia. The clinical and microbiological success is over 70-80% in many series. However, resistant mutants to ceftolozane-tazobactam have been already described. Combination therapies with colistin or meropenem could be among the strategies to avoid the resistance emergence.

PubMed Disclaimer

Conflict of interest statement

JPH has received honoraria as speaker or for advisory activities from Pfizer, MSD, Menarini, Angelini, Zambon. All other authors declare no conflicts of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cho JC, Fiorenza MA, Estrada SJ. Ceftolozane/Tazobactam: A Novel Cephalosporin/ β-Lactamase Inhibitor Combination. Pharmacother J Hum Pharmacol Drug Ther 2015; 35:701–715. Doi: 10.1002/phar.1609. - DOI - PubMed
    1. Yahav D, Giske CG, Grāmatniece A, Abodakpi H, Tam VH, Leibovici L. New β-Lactam–β-Lactamase Inhibitor Combinations. Clin Microbiol Rev 2020;34(1):e00115-20. doi: 10.1128/CMR.00115-20. - DOI - PMC - PubMed
    1. Horcajada JP, Montero M, Oliver A, et al. . Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections. Clin Microbiol Rev 2019; 32(4):e00031-19. doi: 10.1128/CMR.00031-19.. - DOI - PMC - PubMed
    1. Rodríguez-Núñez O, Periañez-Parraga L, Oliver A, et al. . Higher MICs (>2 mg/L) Predict 30-Day Mortality in Patients With Lower Respiratory Tract Infections Caused by Multidrug-and Extensively Drug-Resistant Pseudomonas aeruginosa Treated With Ceftolozane/Tazobactam. Open Forum Infect Dis 2019; 6(10):ofz416. doi: 10.1093/ofid/ofz416. - DOI - PMC - PubMed
    1. Stewart AG, Harris PNA, Chatfield MD, Littleford R, Paterson DL. Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales (“MERINO-3”): study protocol for a multicentre, open-label randomised non-inferior. Trials. 2021;22(1):301. doi: 10.1186/s13063-021-05206-8. - DOI - PMC - PubMed

MeSH terms